All In Biotech

Drug Trial Radar · NCT04703842

Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

A Phase 1/2 Trial of the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Heart Failure With Reduced Ejection Fraction

Last checked: Nov 19, 2026Latest source record: Mar 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

57

Planned (sponsor's estimate)

Start

Sep 23, 2021

Primary completion

Dec 31, 2025

Study completion Dec 2028

Sponsor

Lead sponsor
Sardocor Corp.Industry
Sponsor type
Industry
First posted
Jan 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.

Conditions

  • Congestive Heart Failure
  • Heart Failure, Systolic
  • Heart Failure
  • HFrEF - Heart Failure With Reduced Ejection Fraction

Interventions

  • SRD-001Biological

    AAV1/SERCA2a

  • PlaceboDrug

    SRD-001 matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in symptomatic parametersTime frame: Baseline to Month 6 and Month 12
  2. Change from baseline in symptomatic parametersTime frame: Baseline to Month 6 and Month 12
  3. Change from baseline in physical parameterTime frame: Baseline to Month 6 and Month 12
  4. Change from baseline in LV function/remodelingTime frame: Baseline to Month 6 and Month 12
  5. Rate of recurrent eventsTime frame: Baseline to Month 6 and Month 12
  6. Rate of adverse eventsTime frame: 6 and 12 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • San Diego Cardiac Center

    San Diego, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Washington University in Saint Louis

    St Louis, Missouri · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • University of Washington Medicine

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.